GSA Capital Partners LLP Acquires Shares of 49,145 Arcturus Therapeutics Holdings Inc. $ARCT

GSA Capital Partners LLP bought a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 49,145 shares of the biotechnology company’s stock, valued at approximately $330,000. GSA Capital Partners LLP owned approximately 0.17% of Arcturus Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. AQR Capital Management LLC bought a new stake in shares of Arcturus Therapeutics during the first quarter valued at approximately $128,000. Millennium Management LLC bought a new position in Arcturus Therapeutics in the first quarter worth approximately $4,892,000. Goldman Sachs Group Inc. increased its holdings in Arcturus Therapeutics by 9.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after purchasing an additional 42,636 shares during the period. Acadian Asset Management LLC purchased a new position in Arcturus Therapeutics during the 1st quarter worth $701,000. Finally, Strs Ohio bought a new stake in Arcturus Therapeutics during the 1st quarter valued at $89,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on ARCT. Wall Street Zen upgraded Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, August 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $13.45 on Friday. The firm’s 50 day moving average price is $7.09 and its 200-day moving average price is $7.49. Arcturus Therapeutics Holdings Inc. has a 52-week low of $5.50 and a 52-week high of $24.17. The company has a market cap of $382.25 million, a PE ratio of -4.06 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -3.48 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.